LRMR — Larimar Therapeutics, Inc. Stock Price, Chart & AI Report

Negative Jul 7, 2026 • 22:04 UTC GlobeNewswire Inc. • Pomerantz Llp

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

Pomerantz LLP is investigating potential securities fraud claims against Larimar Therapeutics regarding its nomlabofusp drug candidate for Friedreich's Ataxia. The company's stock fell significantly after disclosing serious safety concerns—anaphylaxis in 7 participants in September 2025 and in 10 of 43 patients by June 2026—despite characterizing the data as 'positive' in press releases.

LRMR securities fraud class action lawsuit Larimar Therapeutics nomlabofusp anaphylaxis Friedreich's Ataxia stock price decline

Sentiment note

The company faces securities fraud investigation for allegedly misrepresenting clinical trial data as 'positive' while concealing serious safety concerns (anaphylaxis in patients). Stock declined 33.66% and 12.57% on two separate announcements, indicating investor loss of confidence and potential regulatory/legal jeopardy.

Positive Feb 26, 2026 • 01:59 UTC Benzinga • Globe Newswire

Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering

Larimar Therapeutics (NASDAQ: LRMR), a clinical-stage biotechnology company, announced the pricing of an upsized underwritten public offering of 20 million shares at $5.00 per share, generating $100 million in gross proceeds. The offering is expected to close on February 27, 2026, with proceeds to be used for development of nomlabofusp and general corporate purposes. J.P. Morgan and Guggenheim Securities are serving as joint bookrunning managers.

LRMR public offering biotechnology Friedreich's ataxia nomlabofusp capital raise rare diseases

Sentiment note

The company successfully upsized its public offering to $100 million, demonstrating investor confidence and providing substantial capital to advance its lead drug candidate nomlabofusp for Friedreich's ataxia treatment and support R&D operations.

Positive Feb 26, 2026 • 01:59 UTC GlobeNewswire Inc. • Na

Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering

Larimar Therapeutics priced an upsized underwritten public offering of 20 million shares at $5.00 per share, generating $100 million in gross proceeds. The company plans to use the funds to support development of nomlabofusp for Friedreich's ataxia and for general corporate purposes. The offering is expected to close on February 27, 2026, with J.P. Morgan and Guggenheim Securities as joint bookrunning managers.

LRMR public offering biotechnology rare diseases nomlabofusp Friedreich's ataxia capital raise clinical-stage

Sentiment note

The company successfully priced an upsized public offering at $5.00 per share, raising $100 million in gross proceeds. This demonstrates investor confidence and provides significant capital to advance their lead drug candidate nomlabofusp development, which has received FDA Breakthrough Therapy Designation. The successful capital raise supports the company's clinical development and commercialization plans.

Negative Oct 16, 2025 • 08:44 UTC Benzinga • Prnewswire

Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LRMR

DJS Law Group is investigating Larimar Therapeutics for potential securities law violations after a clinical study revealed severe allergic reactions, causing the company's stock to drop 33.66%.

LRMR securities fraud clinical study allergic reactions Friedreich's Ataxia

Sentiment note

Stock experienced significant drop after study revealed severe patient reactions, and is now under investigation for potentially misleading investor communications about clinical trial results

Negative Oct 16, 2025 • 01:30 UTC Benzinga • Business Wire

Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – LRMR

DJS Law Group is investigating Larimar Therapeutics for potential securities law violations after a clinical study revealed severe allergic reactions, causing the company's stock to drop 33.66%.

LRMR securities fraud clinical trial allergic reactions Friedreich's Ataxia

Sentiment note

Stock experienced significant drop after study revealed severe patient reactions, and is now under investigation for potentially misleading investor communications about clinical trial results

Negative Oct 16, 2025 • 01:09 UTC Benzinga • Business Wire

LRMR Investors Have Opportunity to Join Larimar Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm is investigating potential securities law violations by Larimar Therapeutics after the company reported study data with severe allergic reactions, causing a significant stock price drop.

LRMR securities law fraud investigation clinical trial allergic reactions

Sentiment note

Company disclosed severe allergic reactions in a clinical study, resulting in a 33.6% stock price decline and potential legal investigation for misleading statements

Negative Sep 29, 2025 • 15:20 UTC Benzinga • Vandana Singh

Larimar Therapeutics Stock Falls After Patients Report Allergic Reaction In Pivotal Study

Larimar Therapeutics reported allergic reactions in a pivotal study for nomlabofusp, a treatment for Friedreich's ataxia. Seven participants experienced anaphylaxis, leading to study modifications and stock price decline.

LRMR Friedreich's ataxia nomlabofusp allergic reaction clinical trial biotechnology

Sentiment note

Stock dropped 25.9% due to safety concerns with anaphylaxis in clinical trial, requiring dosing regimen modifications and potential impact on FDA approval timeline

Positive Sep 29, 2025 • 11:00 UTC GlobeNewswire Inc. • Larimar Therapeutics

Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia

Larimar Therapeutics reported positive results from its ongoing study of nomlabofusp, a potential treatment for Friedreich's Ataxia, showing increased frataxin levels and potential clinical improvements, despite experiencing some anaphylaxis events.

LRMR Friedreich's Ataxia nomlabofusp clinical trial frataxin rare disease

Sentiment note

Demonstrated promising clinical data with increased frataxin levels, potential clinical improvements, ongoing FDA collaboration, and plans for BLA submission in Q2 2026

Neutral Sep 28, 2025 • 21:00 UTC GlobeNewswire Inc. • Larimar Therapeutics

Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia

Larimar Therapeutics will host a conference call to discuss updates on its nomlabofusp clinical development program for treating Friedreich's ataxia, sharing data from an ongoing long-term open label study.

LRMR Friedreich's ataxia clinical development biotechnology rare diseases nomlabofusp

Sentiment note

The company is presenting ongoing research and clinical trial updates, indicating standard progression of a clinical-stage biotechnology company's development efforts

Neutral Aug 14, 2025 • 11:33 UTC The Motley Fool • Na

Larimar Beats Q2 Loss Estimates

Larimar Therapeutics, a clinical-stage biotech firm, reported Q2 2025 results with a narrower net loss of $0.41 per share. The company continues developing nomlabofusp for Friedreich's ataxia, with ongoing clinical trials and FDA engagement for potential accelerated approval in 2026.

LRMR biotechnology rare diseases clinical trials Friedreich's ataxia drug development

Sentiment note

The company showed progress in clinical development, received FDA guidance, and maintained financial runway, but remains pre-revenue with ongoing research expenses

Positive Jul 31, 2025 • 20:15 UTC Benzinga • Globe Newswire

Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Larimar Therapeutics completed a public offering of 21,562,500 common stock shares at $3.20 per share, raising $69.0 million to support drug development and corporate operations.

LRMR biotechnology public offering rare diseases stock issuance

Sentiment note

Successfully raised significant capital ($69.0 million) to fund drug development and pipeline expansion, indicating strong financial positioning and investor confidence

Neutral Jul 30, 2025 • 03:50 UTC GlobeNewswire Inc. • Larimar Therapeutics, Inc.

Larimar Therapeutics Announces Pricing of Underwritten Public Offering

Larimar Therapeutics plans to raise $60 million through a public offering of 18,750,000 common stock shares at $3.20 per share, with proceeds intended to support drug development and corporate operations.

LRMR public offering biotechnology stock fundraising rare diseases

Sentiment note

The company is conducting a standard public offering to raise capital for research and development, which is a typical financing strategy for clinical-stage biotechnology companies